MétaCan
Menu
Back to cohort
Record W2587028803 · doi:10.1093/ecco-jcc/jjx002.454

P329 Effect of adalimumab dose escalation on clinical, health-related quality of life, treatment satisfaction and work productivity outcomes among patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA

2017· article· en· W2587028803 on OpenAlex

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

affAt least one author lists a Canadian institution in the pinned OpenAlex snapshot.

Bibliographic record

VenueJournal of Crohn s and Colitis · 2017
Typearticle
Languageen
FieldMedicine
TopicMicroscopic Colitis
Canadian institutionsUniversity of CalgaryRobarts Clinical Trials
Fundersnot available
KeywordsAdalimumabMedicineUlcerative colitisQuality of life (healthcare)Work productivityProductivityPhysical therapyInternal medicineNursingDisease

Abstract

fetched live from OpenAlex

Background: Although adalimumab (ADA) has been shown to induce and maintain clinical remission in moderate to severe ulcerative colitis (UC), some patients (pts) may lose initial response and could benefit from dose escalation [1]. We assessed the effect of ADA dose escalation on various outcomes among pts with UC in clinical practice. Methods: INSPIRADA was a single-arm, multi-country, open-label study that evaluated the effect of ADA on clinical outcomes, costs of care, treatment satisfaction, and work productivity in pts with UC treated according to usual clinical practice. Adults with active UC, Physician's Global Assessment (PGA) of ≥2, and Short Inflammatory Bowel Disease Questionnaire (SIBDQ) ≤45 at baseline (BL) who failed conventional treatment and who had experienced rectal bleeding ≤7 days of BL were enrolled. Pts received ADA 160/80 mg at Wk 0/2 followed by ADA 40 mg every other week at Wk 4 through Wk 26. Pts who did not respond to ADA by Wk 8 were to discontinue ADA. Pts who lost response at or after Wk 8 could escalate to ADA 40 mg weekly. Outcomes were assessed for pts who dose escalated. Clinical outcomes included Simple Clinical Colitis Activity Index (SCCAI) response (SCCAI decrease ≥2) and remission (defined as an SCCAI ≤2). HRQoL was assessed using SIBDQ and the European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) questionnaire. Satisfaction with medication was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). Work Productivity and Activity Impairment (WPAI) outcomes were determined. Change from BL to Wk 26 in HRQoL, treatment satisfaction, and WPAI outcomes were calculated. Missing data were imputed using nonresponder imputation for response/remission and last observation carried forward for all other outcomes. Results: Data from 129 pts who dose escalated were analysed. At Wk 26, 64% of pts who dose escalated achieved SCCAI response and 33% achieved SCCAI remission (Table 1). Except for work time missed and convenience in TSQM among pts who dose escalated, statistically significant (p<0.001) improvements from BL to Wk 26 were seen in work productivity, performance of daily activities, SIBDQ, EQ-5D-5L, and treatment satisfaction. The safety profile of ADA among pts who dose escalated was consistent with that of pts who did not dose escalate. Conclusions: In pts with UC who lost response, ADA dose escalation was an effective option to recapture response and remission. Significant improvements in HRQoL, treatment satisfaction, and work productivity were also observed. References: [1] Wolf et al, (2014), APT, 40:486–97

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.009
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.112
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0030.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.044
GPT teacher head0.395
Teacher spread0.351 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it